A5007368575- Cancer Immunotherapy and Biomarkers
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Cancer survivorship and care
- Immunotherapy and Immune Responses
- Palliative Care and End-of-Life Issues
- Economic and Financial Impacts of Cancer
- Cancer Diagnosis and Treatment
- Global Cancer Incidence and Screening
- Reproductive Biology and Fertility
- Head and Neck Cancer Studies
- Reproductive Health and Technologies
- Hearing, Cochlea, Tinnitus, Genetics
- Systemic Lupus Erythematosus Research
- Vestibular and auditory disorders
- Lung Cancer Research Studies
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Smoking Behavior and Cessation
- Hearing Loss and Rehabilitation
- Radiomics and Machine Learning in Medical Imaging
- Colorectal Cancer Treatments and Studies
- COVID-19 and healthcare impacts
- Cancer Genomics and Diagnostics
- Lymphoma Diagnosis and Treatment
- Multiple and Secondary Primary Cancers
University School
2022-2025
University Hospitals Seidman Cancer Center
2022-2025
Case Western Reserve University
2021-2025
University Hospitals of Cleveland
2022-2024
Sidney Kimmel Comprehensive Cancer Center
2020-2024
Johns Hopkins University
2020-2024
Case Comprehensive Cancer Center
2023
Memorial Sloan Kettering Cancer Center
2008-2022
Bloomberg (United States)
2020-2022
University of Minnesota
2021
Abstract Studying survivorship and causes of death in patients with advanced or metastatic cancer remains an important task. We characterize the among cancer, across 13 types 25 non-cancer predict risk after diagnosis from diagnosed versus other (e.g., stroke, heart disease, etc.). Among 1,030,937 US (1992–2019) survivors, 82.6% (n = 688,529) died due to while 17.4% 145,006) competing causes. Patients lung, pancreas, esophagus, stomach tumors are most likely die their those prostate breast...
Background Immune-checkpoint inhibitor (ICI)-pneumonitis that does not improve or resolve with corticosteroids and requires additional immunosuppression is termed steroid-refractory ICI-pneumonitis. Herein, we report the clinical features, management outcomes for patients treated intravenous immunoglobulin (IVIG), infliximab, combination of IVIG infliximab Methods Patients ICI-pneumonitis were identified between January 2011 2020 at a tertiary academic center. was defined as radiographic...
Importance Despite a growing population of survivors lung cancer, there is limited understanding the survivorship journey. Survivors cancer experience unmet physical, social, emotional, and medical needs regardless stage at diagnosis or treatment modalities. Objective To investigate association with quality life (QOL) financial toxicity (FT) among cancer. Design, Setting, Participants This survey study was conducted Johns Hopkins Sidney Kimmel Comprehensive Cancer Center thoracic oncology...
Background: Newer therapies prolong survival for patients with lung cancer. Beyond extending survival, the needs of cancer (LC) survivors are poorly described. Methods: We conducted a single-institution assessment survey LC alive ≥1 year from diagnosis. Needs were rated on 5-point Likert scale 4 domains (physical, social, emotional, and medical). Multiple regression models identified demographic or treatment characteristics associated more in each category. A subset analysis metastatic was...
CT45 is a cancer/testis gene that we previously identified by massively parallel signature sequencing. Encoded multigene family on chromosome X, showed restricted mRNA expression to normal testis and various cancers. In this study, monoclonal antibodies were generated against recombinant protein, protein in tumor tissues was evaluated immunohistochemical analysis. adult tissue, testicular germ cells, detected as nuclear mainly at the stage of primary spermatocytes. tumors, correlated with...
We have shown previously that cancer/testis (CT) antigen, CT45, is expressed in various epithelial cancers at a frequency of <5% to ∼35%. In this study, the protein expression CT45 was examined non-Hodgkin B-cell lymphomas and classical Hodgkin lymphoma by immunohistochemical analysis. Serological response also evaluated ELISA using recombinant sera from patients with lymphoma. None 80 low-grade lymphomas, including chronic lymphocytic leukemia/small lymphoma, follicular mantle cell CT45....
Abstract Introduction Anti-PD-(L)1 immune checkpoint inhibitors (ICI) improve survival in patients with advanced non-small cell lung cancer (aNSCLC). The clinical features, survival, and burden of toxicities aNSCLC alive &gt;1 year from ICI initiation are poorly understood. Materials Methods We defined survivors as after start retrospectively reviewed demographics, treatment, immune-related adverse events (irAEs). Long-term irAEs were ongoing lasting year; toxicity measures based on...
Abstract Purpose: Cancer cells recapitulate many behaviors of pluripotent embryonic such as unlimited proliferation, and the capacity to self-renew migrate. Embryo-cancer sequence A (ECSA), later named developmental pluripotency associated-2 (DPPA2), is an gene initially isolated from human preimplantation embryos. We hypothesized that ECSA/DPPA2 would be quiescent in most normal tissues but expressed cancers may therefore a useful target for immunotherapy. Experimental Design: expression...
Patients with certain autoimmune conditions are at a reduced risk of developing breast cancer compared to the general population. Despite this, little is known about outcomes in patients who have concurrent diagnosis.This study differences between women had or did not an diagnosis. The SEER-Medicare databases (2007-2014) were used identify and diagnosis codes those disorder.The studied diseases prevalence 27% among 137,324 cancer. Autoimmune disease was associated significantly longer...
8067 Background: The PACIFIC trial established concurrent chemoradiotherapy (CCRT) followed by consolidation durvalumab as standard of care for unresectable stage III non-small cell lung cancer (NSCLC). This study showed a progression free survival (PFS) 16.9 mo and an overall (OS) 47.5 mo. There is paucity real world data with PACIFIC, especially in diverse patient populations. We present outcomes the regimen NCI-designated comprehensive center (CCC) racially diverse, high poverty catchment...
This cross-sectional study examines e-cigarette use and lung cancer screening uptake among individuals in the US.
Background: Immune checkpoint inhibitors (ICIs) are standard-of-care for patients with advanced non-small cell lung cancer (aNSCLC) and programmed death-ligand 1 (PD-L1) expression ≥ 50%. Methods: A retrospective cohort study was conducted using the US de-identified electronic health record-derived Flatiron Health aNSCLC database (January 1, 2018, to July 31, 2021) among PD-L1 50% initiating first-line ICIs or without chemotherapy. clinical trial-like sub-cohort also identified Eastern...
6572 Background: Broad genomic testing is necessary for treatment of patients with stage IV non-small cell lung cancer (NSCLC). This quality improvement initiative aims to implement a precision medicine service NSCLC at hybrid academic-community practice oncology network. Methods: Following IRB approval, network tumor registries were queried retrospective newly diagnosed from 01/2016 through 12/2018. PREDICT was implemented in 08/2021. It consists of: 1) system-wide reflex by an in-house...
Oncofertility counseling regarding the reproductive risks associated with cancer therapy is essential for quality care. We aimed to increase rate of oncofertility patients age (18-40 years) who were initiating systemic at Johns Hopkins Cancer Center from a baseline 37% (25 68, June 2019-January 2020) 70% by February 2021.